There is a lot of variation in how patients with acute myeloid leukemia (AML) react to the disease, and to its treatment. There are three main approaches to managing AML, and assessing the risks and benefits of each approach is crucial for making treatment decisions. Risk stratification involves assessing a patient’s age, health, and overall underlying conditions.
Guidelines from the American Society of Hematology (ASH) review panel recommend standards of care for individualized acute myeloid leukemia (AML) treatments. For patients with newly diagnosed AML, ASH…
Alice S. Mims, MD, of The Ohio State University’s James Comprehensive Cancer Center, provided an overview of current AML treatment options, such as FLT3 and IDH inhibitors, while…
Mikkael Sekeres, MD, director of the Leukemia Program and vice-chair for Clinical Research at the Cleveland Clinic Taussig Cancer Institute, discusses a phase 2 study of pevonedistat plus azacitidine…
Courtney DiNardo, MD, MSCE, clinical researcher in the Department of Leukemia of the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, presents promising…
Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses the challenges and advancements in treating acute myeloid leukemia (AML) in patients who are unfit for intensive…
In this webcast symposium, Gail J. Roboz, MD, professor of medicine and director of the Clinical and Translational Leukemia Program at the Weill Medical College of Cornell University…
In this interview, Yousef Zakharia, MD, shares thoughts on the topic of expanding acute myeloid leukemia (AML) treatment. Dr. Zakharia discusses up-to-date AML treatments from combination trials such…
